#obesity drugs
Total 2 articles
EconomyEN
Novo Nordisk Loses $50B in One Day: What's Behind the Obesity Drug Crash?
Danish pharma giant Novo Nordisk saw $50 billion wiped off its market value as competition threatens its dominance in the lucrative obesity drug market.
EconomyEN
Novo Nordisk's Cautious 2026 Outlook Signals Obesity Drug Wars Are Just Beginning
Danish pharma giant Novo Nordisk delivered lower-than-expected 2026 guidance, signaling intensifying competition in the obesity drug market as new players challenge Ozempic and Wegovy's dominance.
